Skip to main content
. 2020 Oct 18;11(24):7137–7145. doi: 10.7150/jca.49213

Figure 1.

Figure 1

The correlations between clinicopathological characteristics, hematological markers, clinica response and PFS of the patients with ICIs treatment. A. Numbers of metastasis site affected the PFS for ICIs treatment (P = 0.002). B. CEA levels affected the PFS for ICIs treatment (P = 0.03). C. Serum LDH levels had no significant impacts on PFS for ICIs treatment (P = 0.38). D. Response to ICIs affected the PFS for ICIs treatment (P < 0.001). E. irAE (< G2 / ≥ G2) was associated with PFS for ICIs treatment (P = 0.02). F. irAE (no/any irAE) had no significant impacts on PFS for ICIs treatment (P = 0.107).